Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + enfortumab vedotin
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Sacituzumab tirumotecan + enfortumab vedotin** is a combination of two antibody-drug conjugates being investigated for the treatment of advanced or metastatic urothelial carcinoma. Both are designed to selectively deliver cytotoxic agents to cancer cells expressing their respective targets. Sacituzumab tirumotecan (MK-2870) targets the TROP2 antigen and delivers a camptothecin-derived payload (inhibiting topoisomerase I), while enfortumab vedotin targets Nectin-4 and delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE). The combination is currently being studied in early-phase clinical trials for safety and efficacy in bladder and urothelial cancer patients[1][3][5][9][10].
- Other names
- sacituzumab tirumotecan and enfortumab vedotin
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab tirumotecan + enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + enfortumab vedotin.